Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 7/20 | 0.51 |
| ▸ | PPARG | P37231 | 6/20 | 0.49 |
| ▸ | CTSS | P25774 | 6/20 | 0.47 |
| ▸ | CTSK | P43235 | 6/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1100322 | 1.00 | PPARA (0.51) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL1688831 | 0.88 | CTSK (0.46) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL16020434 | 0.88 | CYP1A2 (0.44) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL4835696 | 0.87 | PPARA (0.49) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL13044371 | 0.87 | CTSK (0.44) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL31385382 | 0.87 | CTSK (0.44) | PPARACTSSCTSKCTSLCTSB | |
| SCHEMBL29401710 | 0.85 | HDAC4 (0.47) | PPARAPPARGCTSSCTSKIDO1 | |
| SCHEMBL22468776 | 0.85 | PPARA (0.50) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL22468774 | 0.85 | PPARA (0.50) | PPARAPPARGCTSSCTSKCTSL | |
| SCHEMBL263105 | 0.84 | PPARA (0.47) | PPARAPPARGCTSSCTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20120172422-A1 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid | ELI LILLY AND COMPANY (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172422-A1 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid | ELI LILLY AND COMPANY (US) | 2012-07-05 | — | — | US | disclosed |
| US-8153683-B2 | Methods of treatment using a prodrug of an excitatory amino acid | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153683-B2 | Methods of treatment using a prodrug of an excitatory amino acid | ELI LILLY AND COMPANY (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-7671082-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2010-03-02 | — | — | US | disclosed |
| US-20080182889-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | MOHER ERIC DAVID | 2008-07-31 | — | — | US | disclosed |
| US-20080182889-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | MOHER ERIC DAVID | 2008-07-31 | — | — | US | disclosed |
| US-7371872-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| US-7371872-B2 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1897550-A2 | Prodrugs of Excitatory Amino Acids | Eli Lilly & Company (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1897550-A2 | Prodrugs of Excitatory Amino Acids | Eli Lilly & Company (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20050222231-A1 | Prodrugs of excitatory amino acids | ELI LILLY AND COMPANY (US) | 2005-10-06 | — | — | US | disclosed |
| EP-1517915-A2 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2005-03-30 | — | — | EP | disclosed |
| WO-2003104217-A2 | PRODRUGS OF EXCITATORY AMINO ACIDS | ELI LILLY AND COMPANY (US) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172422-A1 | Methods of Treatment Using a Prodrug of an Excitatory Amino Acid | SLC1A2, SLC1A1, SLC1A3 | PPARA 2110/4885PPARG 1620/4885CTSS 850/4885 |
| US-20110207672-A1 | METHODS OF TREATMENT USING A PRODRUG OF AN EXCITATORY AMINO ACID | SLC1A2, SLC1A1, SLC1A3 | PPARA 2110/4885PPARG 1620/4885CTSS 850/4885 |
| US-20050222231-A1 | Prodrugs of excitatory amino acids | SLC1A2, SLC1A1, SLC1A3 | PPARA 2014/4885PPARG 1552/4885CTSS 948/4885 |
| US-20080182889-A1 | PRODRUGS OF EXCITATORY AMINO ACIDS | SLC1A2, SLC1A1, SLC1A3 | PPARA 2014/4885PPARG 1552/4885CTSS 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.